| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701930 | Journal of Thoracic Oncology | 2017 | 33 Pages |
Abstract
An EML4-ALK transgenic mouse model for study of drug resistance was successfully established with short duration of tumorigenesis. This model should be a strong preclinical model for testing efficacy of ALK TKIs, providing a useful tool for investigating the mechanisms of acquired resistance and pursuing novel treatment strategies in ALK-positive lung cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Kyoung Ho PhD, Sun Min MD, Hye Ryun MD, Young Hoon PhD, Mi Ran PhD, Sung-Moo PhD, Hwan PhD, Han Na PhD, Ji Min BSc, Sang Gyun BSc, Chae Won PhD, Hyun MD, Hyo Sup MD, Han-Woong PhD, Byoung Chul MD, PhD,